Phone (336) 292-1510
Fax (336) 292-0679

Receive our eNewsletter

  Home  
  Our Team  
  Patient Info  
  Services  

News for Healthier Living

ImmunoPRISM Trial Shows Teclistamab Improves Depth of Response and Progression-Free Survival in High-Risk Smoldering Multiple Myeloma

In a first-of-its-kind randomized trial, Dana-Farber Cancer Institute researchers found that teclistamab may significantly improve outcomes for patients with high-risk smoldering multiple myeloma, a precursor condition that can progress to active cancer.

June 15, 2026


June 16 2026

June 15 2026

June 14 2026

June 13 2026

June 12 2026

June 11 2026

June 10 2026

June 9 2026

June 8 2026

June 7 2026

June 5 2026

June 4 2026

June 3 2026